Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Kura Oncology (KURA)
NASDAQ:KURA
Holding KURA?
Track your performance easily
KURA Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$8.17 - $24.17
Previous Close$17.56
Volume2.00M
Average Volume (3M)519.76K
Market Cap
$1.37B
Enterprise Value$926.86M
Total Cash (Recent Filing)$455.30M
Total Debt (Recent Filing)$16.63M
Price to Earnings (P/E)―
Beta1.61
Next Earnings
Feb 20, 2025EPS Estimate
-$0.66Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.36
Shares Outstanding77,763,750
10 Day Avg. Volume714,340
30 Day Avg. Volume519,758
Standard Deviation0.17
R-Squared0.07
Alpha0.00457
Financial Highlights & Ratios
Price to Book (P/B)3.17
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-7.80
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-6.19
Forecast
1Y Price Target
$28.67Price Target Upside54.39% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
Kura Oncology News
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentsZiftomenib is expected to become the first menin inhibitor under clinical development to treat gastrointestinal stromal tumors, indicating a pioneering role in cancer treatment.
Financial PositionKura reported cash and cash equivalents of $455.3M, with cash runway guidance into 2027, providing a strong financial position for future developments.
New IndicationsPreclinical data supporting ziftomenib's potential for glycemic control in T2D suggests that it might open doors to new metabolic indications, expanding its therapeutic reach beyond oncology.
Bears Say
Financial PerformanceKura reported no revenues for the 3Q24 financial results.
Market SentimentShort Interest (% Float) is at 10.9%.
Product EffectivenessAn inverse dose-efficacy response was observed between the 200mg and 400mg doses of ziftomenib, raising questions about dose effectiveness.
---
Ownership Overview
1.17% Insiders
10.91% Mutual Funds
2.12% Other Institutional Investors
72.96% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
KURA FAQ
What was Kura Oncology’s price range in the past 12 months?
Kura Oncology lowest stock price was $8.17 and its highest was $24.17 in the past 12 months.
What is Kura Oncology’s market cap?
Currently, no data Available
When is Kura Oncology’s upcoming earnings report date?
Kura Oncology’s upcoming earnings report date is Feb 20, 2025 which is in 99 days.
How were Kura Oncology’s earnings last quarter?
Kura Oncology released its earnings results on Nov 07, 2024. The company reported -$0.63 earnings per share for the quarter, missing the consensus estimate of -$0.626 by -$0.004.
Is Kura Oncology overvalued?
According to Wall Street analysts Kura Oncology’s price is currently Undervalued.
Does Kura Oncology pay dividends?
Kura Oncology does not currently pay dividends.
What is Kura Oncology’s EPS estimate?
Kura Oncology’s EPS estimate is -$0.66.
How many shares outstanding does Kura Oncology have?
Kura Oncology has 77,763,750 shares outstanding.
What happened to Kura Oncology’s price movement after its last earnings report?
Kura Oncology reported an EPS of -$0.63 in its last earnings report, missing expectations of -$0.626. Following the earnings report the stock price went down -0.506%.
Which hedge fund is a major shareholder of Kura Oncology?
Among the largest hedge funds holding Kura Oncology’s share is Deerfield Management Company, LP. It holds Kura Oncology’s shares valued at 111M.
---
Kura Oncology Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$28.67 (54.39% Upside)
$28.67 (54.39% Upside)
Blogger Sentiment
Bullish
KURA Sentiment 100%
Sector Average 73%
Sector Average 73%
Hedge Fund Trend
Increased
By 79.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.4%
Last 30 Days ▲ 1.6%
Last 30 Days ▲ 1.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
106.10%
12-Months-Change
Fundamentals
Return on Equity
-46.28%
Trailing 12-Months
Asset Growth
1.07%
Trailing 12-Months
Company Description
Kura Oncology
Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company which engages in the research and development of medicines for the treatment of cancer. Its pipeline includes Tipifarnib which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia; KO-947 which is an ERK inhibitor for MAPK Pathway Tumors; and KO-539 which is a Menin MLL inhibitor for acute leukemias. The company was founded by Troy E. Wilson, Yi Liu, Pingda Ren and Antonio Gualberto on August 22, 2014 and is headquartered in La Jolla, CA.
---
KURA Company Deck
---
KURA Earnings Call
Q3 2024
0:00 / 0:00
---
KURA Stock 12 Month Forecast
Average Price Target
$28.67
▲(54.39% Upside)
Technical Analysis
Best Analysts Covering KURA
1 Year
1 Year Success Rate
18/42 ratings generated profit
1 Year Average Return
+20.07%
reiterated a buy rating 11 months ago
Copying Leah R. Cann's trades and holding each position for 1 Year would result in 42.86% of your transactions generating a profit, with an average return of +20.07% per trade.
---